Compare Sana Biotechnology Inc (SANA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.75 (market cap $1.13B), while Vanguard Total International Stock Index Fund ETF trades at $87.48. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VXUS | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $87.21 |
52-Week Low | $2.68 | $70.87 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
VXUS, the Vanguard Total International Stock ETF, trades at $87.72, up 1.02% on the day, with a bullish technical signal driven by strong moving average alignment. Recent news highlights its role in global diversification, with a 27.82% total return over the past year noted by Seeking Alpha on August 8, 2026. The ETF offers exposure to over 8,700 non-U.S. stocks, attracting institutional interest, though RSI levels suggest potential near-term overbought conditions.
The outlook for VXUS is supported by its valuation discount to U.S. equities and broad diversification benefits, but risks include global economic sensitivity and inflationary pressures. Analyst sentiment is mixed, with some advocating buys for long-term portfolios while others caution on growth-inflation dynamics. Institutional holdings have increased, reflecting confidence in international market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
